Edition:
United States

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

15.98USD
16 Feb 2018
Change (% chg)

$0.42 (+2.70%)
Prev Close
$15.56
Open
$15.52
Day's High
$16.32
Day's Low
$15.52
Volume
476,625
Avg. Vol
641,446
52-wk High
$25.92
52-wk Low
$8.15

Consensus Recommendations

Consensus Recommendation Next Earnings (approx.) Company Fiscal Year
End Month
Last Updated
Outperform 0.20 December 19 Feb 2018

Analyst Recommendations and Revisions

1-5 Linear Scale Current 1 Month
Ago
2 Month
Ago
3 Month
Ago
(1) BUY 2 2 2 2
(2) OUTPERFORM 1 1 1 1
(3) HOLD 0 0 0 0
(4) UNDERPERFORM 1 1 1 1
(5) SELL 0 0 0 0
No Opinion 0 0 0 0
Mean Rating 2.00 2.00 2.00 2.00

Consensus Estimates Analysis

Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
  # of Estimates Mean High Low 1 Year
Ago
SALES (in millions)
Quarter Ending Mar-18 3 58.90 62.20 55.00 37.22
Quarter Ending Jun-18 3 67.37 69.30 64.82 39.38
Year Ending Dec-18 4 265.25 290.00 219.95 171.35
Earnings (per share)
Quarter Ending Mar-18 3 0.20 0.22 0.16 0.08
Quarter Ending Jun-18 3 0.24 0.26 0.22 0.09
Year Ending Dec-18 4 0.92 1.06 0.71 0.41
LT Growth Rate (%) 1 71.00 71.00 71.00 --

Historical Surprises

Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Estimates vs Actual Estimate Actual Difference Surprise %
SALES (in millions)
Quarter Ending Sep-17 42.46 42.76 0.30 0.71
Quarter Ending Jun-17 32.53 35.56 3.03 9.32
Quarter Ending Mar-17 25.53 27.60 2.07 8.11
Quarter Ending Dec-16 23.80 23.81 0.01 0.06
Quarter Ending Sep-16 21.24 21.73 0.49 2.29

Consensus Estimates Trend

Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
  Current 1 Week
Ago
1 Month
Ago
2 Month
Ago
1 Year
Ago
SALES (in millions)
Quarter Ending Mar-18 58.90 58.90 58.05 58.05 37.22
Quarter Ending Jun-18 67.37 67.37 62.11 62.11 39.38
Year Ending Dec-18 265.25 265.25 240.47 240.47 171.35

Estimates Revisions Summary

  Last Week Last 4 Weeks
Number Of Revisions: Up Down Up Down
Revenue
Quarter Ending Mar-18 0 0 1 0
Quarter Ending Jun-18 0 0 1 0
Year Ending Dec-18 0 0 2 0
Earnings